Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



FACTORS AFFECTING BIOCHEMICAL RECURRENCE TIME IN PROSTATE CANCER PATIENTS: A SINGLE CENTER ANALYSIS

Sedef GÖKHAN AÇIKGÖZ,İpek Pınar ARAL,Hüseyin Furkan ÖZTÜRK,Süheyla AYTAÇ ARSLAN,Havva BEYAZ,Gonca ALTINIŞIK İNAN,Yılmaz TEZCAN.




Abstract
Cited by 0 Articles

ABSTRACT

Objective: In this study, patients who underwent salvage Radiotherapy (RT) after biochemical recurrence (BCR) were evaluated retrospectively. The aim of this study was to evaluate the factors affecting the time to biochemical recurrence and salvage RT after radical prostatectomy.

Materials and Methods: In XXX Hospital, patients with prostate cancer who received salvage RT between 01.01.2011 and 01.01.2018 were analyzed retrospectively. Patients who had undergone radical prostatectomy for prostate adenocarcinoma, and received salvage RT for PSA (Prostate-specific antigen) recurrence, were included. Patients who received post-surgery hormone therapy, and received definitive or palliative RT, were excluded. SPSS Ver. 22 software package was used for statistical analysis and the statistical significance limit was accepted as p≤0.05.

Results: Results of 84 patients who met the criteria of the study were analyzed. The median follow-up was 78.5 (range 28-172) months and the median time between surgery and RT was 23.7 (range 5.1-136.9) months. The relationship between the time from surgery to BCR and the GS was statistically significant; the median time was 16.3 (2.17-125.9) months in the group with GS ≤8, and 8.9 (2.8-20.3) months in the group with GS 9-10 (p=0.05). The relationship between the time from surgery to BCR and T stage was statistically significant. In subgroup analysis, this difference was seen between T3A and T3B stages. That time was 17.8 (range 2.17-73.77) months in T3A and 8.7 (range 2.8-29.6) months in T3B stages (p=0.02). The relationship between the level of nadir PSA and the median time between surgery and BCR was significant. It was median 20.6 (range 5.4-65.2) months in patients with PSA< 0.03 and 8.8 (range 2.2-125.9) months in patients with PSA ≥0.03 (p

Key words: Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.